Neurotrophic keratitis is a degenerative corneal disease caused by impairment of corneal sensory innervation. It is characterized by decreased or absent corneal sensation, leading to epithelial breakdown, impairment of healing, and ultimately to the development of corneal ulceration, melting and perforation. This condition was initially described as neuroparalytic keratitis: Magendie demonstrated this condition experimentally in 1824.
Ocular and systemic conditions associated with damage at any level to the fifth cranial nerve, from the Trigeminal nucleus to the corneal nerve endings may lead to the development of neurotrophic keratitis. The most common causes include herpetic keratitis, chemical burns, long-term use of contact lenses, corneal surgery, ablative procedures for trigeminal neuralgia, and surgical procedures for reduction of jaw fractures. Other less frequent causes are space-occupying intracranial masses (e.g., schwannoma, meningioma and aneurysms) that can lead to compression of the nerve and reduce corneal sensitivity. Systemic diseases that may compromise trigeminal function like diabetes, multiple sclerosis and Leprosy may lead to the development of neurotrophic keratitis. Presence of neurotrophic keratitis in children is rare and may be seen in association with congenital syndromes like Riley-Day syndrome, Goldenhar- Gorlin syndrome, Mobius syndrome, Familial corneal hypesthesia and Congenital Insensitivity to Pain with Anhidrosis
Neurotrophic keratitis is considered to be a rare disease with an estimated prevalence of less than 5/10,000. It is estimated that neurotrophic keratitis affects 6% of herpetic keratitis cases, 12.8% of Herpes zoster keratitis cases and 2.8% of patients who underwent surgical procedures for Trigeminal neuralgia.
Corneal nerves play an important role in maintaining corneal epithelial integrity, proliferation and wound healing. It has been postulated that corneal sensory nerve damage leads to marked changes in levels of neuromodulators, that cause impairment in epithelial cell vitality and metabolism of the epithelial cells. This can affect mitosis of epithelial cells and consequently lead to an epithelial breakdown. There is an associated reduction in lacrimation reflex with sensory nerve involvement, which can worsen the damage. The corneal epithelium thickness is decreased, and epithelial cells show intracellular swelling, loss of microvilli, and an abnormal production of the basal lamina. The resulting morphological and metabolic epithelial disturbances lead to the development of recurrent or persistent epithelial defects, which can progress to corneal ulceration, melting and perforation. A large number of chemical mediators have been postulated to play a role in the development of neurotrophic keratitis including nerve growth factor, Substance P, neuropeptide Y, Calcitonin gene-related peptide, Galanin, and Acetylcholine.
Patients with Neurotrophic keratitis rarely complain of symptoms, probably due to their lack of corneal sensation. Occasionally, however, they may present with redness and blurring of vision. The blurring of vision can occur due to persistent epithelial defects, corneal edema, or scarring. Antecedent episodes of redness and eye pain or the presence of cutaneous blistering or scarring suggest previous herpetic infections. A history of corneal trauma, surgery, chemical burns, long-term use of topical medications, neurosurgical procedures, or diabetes may be obtained.
The hallmark of this disease is reduced or absent corneal sensation. Neurotrophic keratitis can be classified into three stages according to the Mackie classification. This staging is based on the severity of corneal damage, increasing from stage 1 to stage 3.
In summary, staging of neurotrophic keratitis is characterized by epithelial changes (stage 1), persistent epithelial defects (stage 2), and corneal ulcer (stage 3).
The diagnosis is frequently suspected by the patient’s history associated with trigeminal impairment, presence of persistent epithelial defects or ulcers, and decreased corneal sensitivity. The presence of systemic diseases (such as Diabetes Mellitus), medication use (like neuroleptics), and corneal causes (like contact lens abuse, chemical burns, etc. ) must be evaluated. Clinical evaluation of different cranial nerve functions may help in localization of the site of the lesion. Associated seventh or eighth nerve palsy may be an indication of acoustic neuroma or its surgical resection causing trigeminal nerve damage. Associated third, fourth, and sixth nerve palsy may point to a cavernous sinus pathology.
Assessment of the cornea includes a quantitative evaluation of decreased corneal sensation using a Cochet-Bonnet or no-contact gas esthesiometer.
Slit lamp examination can be of great help for identifying the characteristic corneal lesions and for sector iris atrophy, which is characteristic of herpetic infections. An ulcer, if seen, requires microbiological examination to rule out an infection.
Dilated fundus examination may reveal pale or swollen optic disc in cases of intracranial tumors with trigeminal compression. Tear film function should be evaluated because decreased corneal sensitivity may alter the tear film and trigger a vicious circle in which tear film dysfunction worsens the prognosis of neurotrophic keratitis. The eyelids need to be examined, both for diagnostic and prognostic reasons. Lagophthalmos would exacerbate the changes seen in neurotrophic keratitis.
Early diagnosis, treatment and careful monitoring of neurotrophic keratitis patients are mandatory to achieve epithelial healing and prevent progression of corneal damage.
The use of preservative-free artificial tears may help improve the corneal surface at all stages of disease severity.
In the event of stromal melting, use of topical collagenase inhibitors, such as N-acetylcysteine, and systemic administration of tetracycline or medroxyprogesterone may be considered. Use of topical antibiotic eye drops to prevent infection in eyes with neurotrophic keratitis at stages 2 and three are recommended. Topical nerve growth factor (NGF) and autologous serum eye drops are considered as promising treatments of neurotrophic keratopathy.
Surgical treatments are reserved for refractory cases. They include partial or total tarsorrhaphy, amniotic membrane transplantation, conjunctival flap, and Botulinum A toxin injection of the eyelid elevator muscle.
The prognosis of neurotrophic keratitis depends on the cause and severity of the trigeminal damage and the presence of associated ocular surface disease. It is accepted that the more severe the corneal sensory impairment, the higher the probability of neurotrophic keratitis progression. All the current therapeutic approaches focus on preventing the disease progression, but there are none to improve the corneal sensation and visual acuity. However, use of topical nerve growth factor derivatives and an Ergoline derivative, called Nicergoline are promising approaches in improving corneal sensation and thus extremely beneficial in patients who fail to respond to conventional therapy.
Neurotrophic keratitis is best managed by an interprofessional team that also includes the ophthalmology nurse.
Clinicians should be aware that patients with neurotrophic keratitis rarely complain of symptoms, probably due to their lack of corneal sensation. Occasionally, however, they may present with redness and blurring of vision. The blurring of vision can occur due to persistent epithelial defects, corneal edema, or scarring. Antecedent episodes of redness and eye pain or the presence of cutaneous blistering or scarring suggest previous herpetic infections. History of corneal trauma, surgery, chemical burns, long-term use of topical medications, neurosurgical procedures, or diabetes may be obtained. Once the disorder is suspected, a prompt referral to an ophthalmologist is necessary.
Early treatment can help prevent the worsening of the corneal injury.
|||Neurotrophic keratitis., Semeraro F,Forbice E,Romano V,Angi M,Romano MR,Filippelli ME,Di Iorio R,Costagliola C,, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2014 [PubMed PMID: 24107451]|
|||Neurotrophic keratitis., Bonini S,Rama P,Olzi D,Lambiase A,, Eye (London, England), 2003 Nov [PubMed PMID: 14631406]|
|||Diagnosis and management of neurotrophic keratitis., Sacchetti M,Lambiase A,, Clinical ophthalmology (Auckland, N.Z.), 2014 [PubMed PMID: 24672223]|
|||Treatment of neurotrophic keratopathy with nicergoline., Lee YC,Kim SY,, Cornea, 2015 Mar [PubMed PMID: 25625360]|
|||Pérez-Bartolomé F,Mingo Botín D,de Dompablo E,de Arriba P,Arnalich Montiel F,Muñoz Negrete FJ, Post-herpes neurotrophic keratopathy: Aetiopathogenesis, clinical signs and current therapies. Archivos de la Sociedad Espanola de Oftalmologia. 2019 Apr; [PubMed PMID: 30718014]|
|||Voelker R, New Drug Treats Rare, Debilitating Neurotrophic Keratitis. JAMA. 2018 Oct 2; [PubMed PMID: 30285163]|
|||Scanzera AC,Shorter E, Case Series: Management of Neurotrophic Keratitis from Familial Dysautonomia. Optometry and vision science : official publication of the American Academy of Optometry. 2018 Aug; [PubMed PMID: 30063663]|
|||Versura P,Giannaccare G,Pellegrini M,Sebastiani S,Campos EC, Neurotrophic keratitis: current challenges and future prospects. Eye and brain. 2018; [PubMed PMID: 29988739]|
|||Gheorghe A,Rosoga AT,Mrini F,Vărgău I,Gherghiceanu F, Various therapies for ocular surface diseases. Romanian journal of ophthalmology. 2018 Jan-Mar; [PubMed PMID: 29796439]|